NPCE Stock Analysis: Buy, Sell, or Hold?
NPCE - Neuropace, Inc. Common Stock
$14.65
0.58 (4.12%)
▲
5d:
+7.25%
30d:
+5.02%
90d:
-5.12%
BUY
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 12, 2026
Get Alerted When NPCE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NPCE shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: NPCE shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: NPCE is currently trading at $14.65, which is considered extended relative to its 30-day fair value range of $13.36 to $14.48.
Technical Outlook: Technically, NPCE is in a downtrend. The price is approaching resistance at $14.50. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.1% recently.
Market Sentiment: NPCE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $19.88 (+35.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NPCE is in a downtrend. The price is approaching resistance at $14.50. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.1% recently.
Market Sentiment: NPCE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $19.88 (+35.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$13.36 -
$14.48
Company Quality Score
60/100
(BUY)
Options IV Signal
50th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
68.8%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Options fairly priced (IV 50th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.1%)
- BULLISH: Trading 35.7% below Wall St target ($19.88)
Fair Price Analysis
30-Day Fair Range
$13.36 -
$14.48
Current vs Fair Value
EXTENDED
Expected Move (7 Days)
±$2.05
(14.0%)
Support & Resistance Levels
Support Level
$12.47
Resistance Level
$14.50
Current Trend
Downtrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-41.47
Wall Street Target
$19.88
(+35.7%)
Revenue Growth (YoY)
23.9%
Profit Margin
-21.5%
Share & Embed Analysis
Last updated: April 02, 2026 6:43 PM ET
Data refreshes hourly during market hours. Next update: 7:43 PM
Data refreshes hourly during market hours. Next update: 7:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NPCE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$102 | 60 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$424 | 61 BUY |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$133 | 59 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$86 | 47 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$111 | 62 BUY |
